SCHEMBL3943499

SCHEMBL3943499

O=C(Nc1ccc(Cl)cc1)Nc1cccc(C(=O)N2CCOCC2)c1

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 7/20 0.80
ALDH1A1 P00352 3/20 0.78
HPGD P15428 3/20 0.78
HTT P42858 3/20 0.78
MAPT P10636 3/20 0.78
NPC1 O15118 2/20 0.78
SMN1; SMN2 Q16637 2/20 0.78
LMNA P02545 1/20 0.78
TP53 P04637 2/20 0.74
RAB9A P51151 2/20 0.62
PHGDH O43175 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP3A5 P20815 1/20 0.58
MEN1 O00255 1/20 0.57
POLB P06746 1/20 0.57
KMT2A Q03164 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3937371 0.89 EPHX2 (1.00) EPHX2ALDH1A1HPGDHTTMAPT
SCHEMBL4553920 0.89 HTT (0.69) EPHX2ALDH1A1HPGDHTTMAPT
SCHEMBL27308605 0.89 NPC1 (0.75) EPHX2ALDH1A1HPGDHTTMAPT
SCHEMBL3937303 0.87 EPHX2 (0.77) EPHX2ALDH1A1HPGDHTTMAPT
SCHEMBL27312313 0.85 EPHX2 (0.64) EPHX2ALDH1A1HPGDHTTMAPT
SCHEMBL3347907 0.85 EPHX2 (1.00) EPHX2ALDH1A1HPGDHTTMAPT
SCHEMBL27311975 0.83 EPHX2 (0.70) EPHX2ALDH1A1HPGDHTTMAPT
SCHEMBL4084025 0.82 HPGD (0.60) EPHX2ALDH1A1HPGDHTTMAPT
SCHEMBL6992760 0.81 ALDH1A1 (0.64) EPHX2ALDH1A1HPGDHTTMAPT
SCHEMBL27763478 0.81 EPHX2 (0.73) EPHX2ALDH1A1HPGDHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046329-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS Arete Therapeutics, INC. (US) 2009-04-15 EP claimed
WO-2008016884-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-02-07 WO claimed
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-02-07 US claimed
CN-101495119-A Soluble epoxide hydrolase inhibitors ARETE THERAPEUTICS INC (US) 2009-07-29 CN disclosed
EP-2046329-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS Arete Therapeutics, INC. (US) 2009-04-15 EP disclosed
WO-2008016884-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-02-07 WO disclosed
WO-2008016884-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-02-07 WO disclosed
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-02-07 US disclosed
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-02-07 US disclosed
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 EPHX2 2/4885ALDH1A1 586/4885HPGD 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.